[1] SINGER M,DEUTSCHMAN C S,SEYMOUR C W,et al.The third international consensus definitions for sepsis and septic shock(Sepsis-3)[J].JAMA,2016,315(8):801-810.
[2] RUDD K E,JOHNSON S C,AGESA K M,et al.Global,regional,and national sepsis incidence and mortality,1990-2017:analysis for the Global Burden of Disease Study[J].Lancet,2020,395(10219):200-211.
[3] GRANDE E,GRIPPO F,FROVA L,et al.The increase of sepsis-related mortality in Italy:a nationwide study,2003-2015[J].Eur J Clin Microbiol Infect Dis,2019,38(9):1701-1708.
[4] MACHADO F R,CAVALCANTI A B,BOZZA F A,et al.The epidemiology of sepsis in Brazilian intensive care units(the Sepsis PREvalence Assessment Database,SPREAD):an observational study[J].Lancet Infect Dis,2017,17(11):1180-1189.
[5] XIE J,WANG H,KANG Y,et al.The epidemiology of sepsis in Chinese ICUs:a national cross-sectional survey[J].Crit Care Med,2020,48(3):e209-e218.
[6] 中国医疗保健国际交流促进会急诊医学分会,中华医学会急诊医学分会,中国医师协会急诊医师分会,等.中国脓毒症早期预防与阻断急诊专家共识[J].中华急诊医学杂志,2020,29(7):885-895.
[7] DARDEN D B,KELLY S,FENNER B P,et al.Dysregulated immunity and immunotherapy after sepsis[J].J Clin Med,2021,10(8):1742.
[8] VAN DER POLL T,VAN DE VEERDONK F L,SCICLUNA B P,et al.The immunopathology of sepsis and potential therapeutic targets[J].Nat Rev Immunol,2017,17(7):407-420.
[9] HUANG M,CAI S,SU J.The pathogenesis of sepsis and potential therapeutic targets[J].Int J Mol Sci,2019,20(21):5376.
[10] VALLES P G,GIL LORENZO A F,GARCIA R D,et al.Toll-like receptor 4 in acute kidney injury[J].Int J Mol Sci,2023,24(2):1415.
[11] VENET F,MONNERET G.Advances in the understanding and treatment of sepsis-induced immunosuppression[J].Nat Rev Nephrol,2018,14(2):121-137.
[12] STRNAD P,TACKE F,KOCH A,et al.Liver-guardian,modifier and target of sepsis[J].Nat Rev Gastro Hepatol,2017,14(1):55-66.
[13] PATEL J J,TANEJA A,NICCUM D,et al.The association of serum bilirubin levels on the outcomes of severe sepsis[J].J Intensive Care Med,2015,30(1):23-29.
[14] OTTO G P,SOSSDORF M,CLAUS R A,et al.The late phase of sepsis is characterized by an increased microbiological burden and death rate[J].Crit Care,2011,15(4):R183.
[15] WILSKE F,SKORUP P,HANSLIN K,et al.Enhanced bacterial clearance in early secondary sepsis in a porcine intensive care model[J].Sci Rep,2023,13(1):1964.
[16] ALLEGRA A,MIRABILE G,ETTARI R,et al.The impact of curcumin on immune response:an immunomodulatory strategy to treat sepsis[J].Int J Mol Sci,2022,23(23):14710.
[17] GENTILE L F,MOLDAWER L L.DAMPs,PAMPs,and the origins of SIRS in bacterial sepsis[J].Shock,2013,39(1):113-114.
[18] RAI V,MATHEWS G,AGRAWAL D K.Translational and clinical significance of DAMPs,PAMPs,and PRRs in trauma-induced inflammation[J].Arch Clin Biomed Res,2022,6(5):673-685.
[19] PRESCOTT H C,ANGUS D C.Enhancing recovery from sepsis:a review[J].JAMA,2018,319(1):62-75.
[20] 李强,邱玥,肖国辉.ICU脓毒症患者血清丙二醛、超氧化物歧化酶水平及SOFA评分与预后的关系[J].现代医学,2020,48(10):1325-1328.
[21] MILLER T,EMAMIAN N,GLICK Z,et al.Association between resuscitation in the critical care resuscitation unit and in-hospital mortality[J].Am J Emerg Med,2022,60:96-100.
[22] WEINBERGER J,KLOMPAS M,RHEE C.What is the utility of measuring lactate levels in patients with sepsis and septic shock?[J].Semin Respir Crit Care Med,2021,42(5):650-661.
[23] GAUER R,FORBES D,BOYER N.Sepsis:diagnosis and management[J].Am Fam Physician,2020,101(7):409-418.
[24] BASODAN N,AL MEHMADI A E,AL MEHMADI A E,et al.Septic shock:management and outcomes[J].Cureus,2022,14(12):e32158.
[25] 房延儒,杨立山,李强,等.单核细胞分布宽度对成人脓毒症患者诊断价值的Meta分析[J].中国急救医学,2022,42(9):769-773.
[26] AGNELLO L,VIDALI M,SASSO B L,et al.Monocyte distribution width(MDW) as a screening tool for early detecting sepsis:a systematic review and meta-analysis[J].Clin Chem Lab Med,2022,60(5):786-792.
[27] HAUSFATER P,ROBERT B N,MORALES I C,et al.Monocyte distribution width(MDW) performance as an early sepsis indicator in the emergency department:comparison with CRP and procalcitonin in a multicenter international European prospective study[J].Crit Care,2021,25(1):227.
[28] JOSHI I,CARNEY W P,ROCK E P.Utility of monocyte HLA-DR and rationale for therapeutic GM-CSF in sepsis immunoparalysis[J].Front Immunol,2023,14:1130214.
[29] LUKASZEWICZ A C,GRIENAY M,RESCHE-RIGON M,et al.Monocytic HLA-DR expression in intensive care patients:interest for prognosis and secondary infection prediction[J].Crit Care Med,2009,37(10):2746-2752.
[30] RODRIGUEZ-ROSALES Y A,KOX M,VAN RIJSSEN E,et al.Long-term effects of experimental human endotoxemia on immune cell function:similarities and differences with sepsis[J].Shock,2019,51(6):678-689.
[31] LASSEAUX C,FOURMAUX M P,CHAMAILLARD M,et al.Type I interferons drive inflammasome-independent emergency monocytopoiesis during endotoxemia[J].Sci Rep,2017,7(1):16935.
[32] HEUMANN D,GLAUSER M P,CALANDRA T.Monocyte deactivation in septic shock[J].Curr Opin Infect Dis,1998,11(3):279-283.
[33] HEINZELMANN M,MERCER-JONES M,CHEADLE W G,et al.CD14 expression in injured patients correlates with outcome[J].Ann Surg,1996,224(1):91-96.
[34] SCHINKEL C,SENDTNER R,ZIMMER S,et al.Functional analysis of monocyte subsets in surgical sepsis[J].J Trauma,1998,44(5):743-748;discussion 748-749.
[35] PATEL A A,ZHANG Y,FULLERTON J N,et al.The fate and lifespan of human monocyte subsets in steady state and systemic inflammation[J].J Exp Med,2017,214(7):1913-1923.
[36] 陈国昇,文大林,种慧敏,等.外周血单核细胞亚群及CD64表达水平对脓毒症诊断和预后评估的价值[J].中华危重病急救医学,2022,34(9):921-926.
[37] CHUNG H,LEE J H,JO Y H,et al.Circulating monocyte counts and its impact on outcomes in patients with severe sepsis including septic shock[J].Shock,2019,51(4):423-429.
[38] ZHAO Q,GONG Z,WANG J,et al.A zinc-and calcium-rich lysosomal nanoreactor rescues monocyte/macrophage dysfunction under sepsis[J].Adv Sci(Weinh),2023,10(6):e2205097.
[39] IKEGAME A,KONDO A,KITAGUCHI K,et al.Presepsin production in monocyte/macrophage-mediated phagocytosis of neutrophil extracellular traps[J].Sci Rep,2022,12(1):5978.
[40] XU J,GAO C,HE Y,et al.NLRC3 expression in macrophage impairs glycolysis and host immune defense by modulating the NF-kappaB-NFAT5 complex during septic immunosuppression[J].Mol Ther,2023,31(1):154-173.
[41] RAJAEE A,BARNETT R,CHEADLE W G.Pathogen-and danger-associated molecular patterns and the cytokine response in sepsis[J].Surg Infect(Larchmt),2018,19(2):107-116.
[42] WU Z,DENG J,ZHOU H,et al.Programmed cell death in sepsis associated acute kidney injury[J].Front Med(Lausanne),2022,9:883028.
[43] ZHANG B W,MOORLAG S J,DOMINGUEZ-ANDRES J,et al.Single-cell RNA sequencing reveals induction of distinct trained-immunity programs in human monocytes[J].J Clin Invest,2022,132(7):e147719.
[44] DELANO M J,WARD P A.Sepsis-induced immune dysfunction:can immune therapies reduce mortality?[J].J Clin Invest,2016,126(1):23-31. |